Full history for every metric is available with a Kvantra account
Harpoon Therapeutics, Inc. (HARP)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 5 | 6 | 17 | 24 | 32 | 37 |
| Operating profit | $m | -68 | -39 | |||||
| Net profit | $m | -17 | -27 | -52 | -46 | -166 | -67 | -31 |
| EPS reported | $ | -20.24 | -8.79 | |||||
| Operating cashflow per share | $ | -26.89 | -26.89 | |||||
| Capex per share | $ | 0.10 | 0.10 | |||||
| FCF per share | $ | -26.99 | -26.99 | |||||
| Free cash flow | $m | -90 | -69 | |||||
| Net debt | $m | -37 | -32 | |||||
| Book value equity | $m | 5 | 5 | |||||
| Book value per share | $ | 1.63 | 1.15 | |||||
| Number of shares | m | 3.32 | 3.95 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.46 | 190.50 | |||||
| P/S LTM | x | 0.75 | 23.17 | |||||
| P/FCF LTM | x | -0.27 | -12.45 | |||||
| EV/EBITDA LTM | x | 0.17 | -28.08 | |||||
| EV/Sales LTM | x | -0.36 | 22.32 | |||||
| Earnings Yield LTM | % | -278.81% | -87.97% | |||||
| FCF Yield | % | -371.81% | -8.03% | |||||
| Quality | ||||||||
| ROE | % | -1243.5% | -211.56% | |||||
| ROIC | % | -285.53% | -285.53% | |||||
| Operating margin | % | -214.08% | -214.08% | |||||
| Gross margin | % | 90.30% | 90.30% | |||||
| FCF/Sales | % | -280.52% | -280.52% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +34.92% | +16.14% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -5.59 | -4.79 | |||||
| Net Debt/EBITDA | x | 0.54 | 0.54 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -154.10% | -3.65% | |||||
| Net debt/Equity | x | -6.87 | -6.96 | |||||
| Gross debt/equity | x | 2.96 | 3.19 | |||||
Company overview
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Harpoon Therapeutics, Inc. (HARP)
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free